Barclays analyst Mark Devries maintains Mr. Cooper Gr (NASDAQ:COOP) with a Equal-Weight and raises the price target from $41 to $48.
Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
